HomeAbout usNewsResearchContactsRussianEnglish

April 2017

Amhion company congratulates our scientific consultant and one of the company founders, Doctor of Sciences, Professor, Shtilman Mikhail Isaakovich on his 80th anniversary!


February 2016

Amhion company together with Medical faculty of Otto von Guericke Magdeburg University (Germany), Arivis (Germany), ToxPlus (Greece) and Drugs Technology (Russia) started international project NABUCO: Nanoparticles for Brain Use, Diagnostic and Ophthalmological Applications organized in frames of ERANET RUS PLUS program.


December 2015

Our company wishes you a Happy New Year! On behalf of all employees wish you prosperity and happiness in the New Year and good health and success in all your deeds!


Phone: (499) 972-48-08
Fax: (495) 609-29-64

Rambler's Top100

High-performance nanoscale forms of biologically active and medical substances

New Amphidon nanocarriers based on a series of original amphiphilic polymers allow for production of high-performance forms of medical and bio-active substances for use in medicine, beauty industry, agriculture and biotechnology.

The new products use polymer nanoparticles as containers that can be loaded with medical and bio-active substances and target-delivered to the nidus of infection. Gradual and controlled discharge of the active agent from the nanoparticles during the period of several hours or even days make it possible to replace an entire course of drug administration with a one-time delivery of the medical substance to the infected area.

We have developed a simple and original technology for producing nanocontainers based on synthetic polymers that have been long and successfully used in medicine and pharmacology as blood substitutes, etc. This approach guarantees higher safety of new drugs while at the same time lowering their production cost compared to that of currently developed analogues and thus making them highly commercially viable.

The nanoscale capsules created by us can be loaded with bioactive and medical substances that will be target-delivered and discharged in the human body. The capsules have a comprehensive range of properties that can be used as a basis for developing high-performance solutions for diagnosis and treatment:

  • Average particle size from 20 to 300 nm;
  • Close spread of particles by size;
  • Spherical form;
  • High load capacity (up to 80 %);
  • Low toxicity;
  • High compatibility with blood components;
  • No interference with blood viscosity parameters;
  • Biocompatibility;
  • Good resistance during long storage periods;
  • High mechanical and chemical resistance;
  • Low cost and ease of production.

Inserting bioactive and medical substances into nanoparticles based on our amphiphilic polymers makes it possible to:

  • Ensure solubility in water of non-soluble or poorly soluble drugs (i.e. to make it possible to deliver them using injection or by other means);
  • Ensure prolonged and controlled discharge of the active agent;
  • Lower toxicity and other side effects of the drug;
  • Ensure targeted delivery of the drug to the nidus of infection by loading the polymer with additional functional groups and linking them with marker groups and molecules;
  • Overcome protective barriers of the body and guarantee the acquisition of the drug by the cells of reticuloendothelian system;
  • Decrease therapeutic doses of the active agent while simultaneously increasing their efficacy;
  • Produce additional immunostimulating effect on the body provided by the polymer carriers own activity;
  • Provide a high loading capability for drug insertion (up to 80 %), making the production profitable;
  • Lower the bodys resistance to the drug.

The importance of nanoscale delivery systems for pharmaceutical industry:

  • Research and development of new delivery systems and of drug forms based on such systems is considerably cheaper than research and development of new active molecules;
  • Decreasing the volume of drug in the medical device while increasing its efficacy lowers the cost of its production;
  • Original delivery systems will increase the commercial potential of the drug by differentiating it from the analogues;
  • New nanoparticle delivery systems may give fresh impetus to using old, well-known drugs (resurrection of the drug);
  • Polymer nanoscale form will allow to use advanced drugs that were of limited use before due to their poor solubility in aqueous environments.

It has been proven so far that the following drugs can be inserted into the nanoparticles of our design:

  • Anti-inflammatory Indometacin and Dyclofenac;
  • Antineoplastic Doxorubicin, Angiostatin, Cysplatin;
  • Anti-tuberculosis Rhyphampicin;
  • Antimycotic Nistatin, Amphotericin ;
  • Hepatoprotective Silimarin;
  • Bioactive proteins BBI proteinase inhibitor, IX blood factor.
Amphotericin B poorly soluble antimycotic antibiotic, located on the surface and walls of the bubble (Figure A).

Comparison (Figure B): an equal quantity of Amphotericin B is inserted inside polymer nanoparticles, a hydrocompatible form of antibiotic is obtained.
Effect of different drug delivery forms of Angiostatin antineoplastic on the growth of cancer tumor in laboratory mice.

Our product is on the frontline of research in the development of modern pharmaceutical industry and can lead to creation of an entire range of innovative high-performance solutions for diagnosis and treatment that do not have any direct analogues and are highly competitive, commercially viable and possessing a definitive investment appeal for application in pharmaceutics, biotechnology, cosmetics and agriculture.